Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin for Cognitive Impairment in Schizophrenia
NCT03271866Unknown
- Sponsor
- Central South University
- Start
- Aug 2017
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of metformin in schizophrenia (2 arms), sponsored by Central South University. Primary endpoint: MATRICS Consensus Cognitive Battery Composite Score at 12 weeks. Status: unknown.
02
Drugs
metformin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT03271866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03271866.